Sean Kendall focuses on identifying and evaluating new life science technologies and provides operating assistance to early-stage portfolio companies. He contributed to the formation and investment into Vizgen and other companies in development. He supported investments in Encodia and Singleron Biotechnologies, and has contributed to business efforts at Twist Bioscience and Genuity Science. He sits as a board observer at Vizgen, Encodia, and others, having previously served as an observer at Twist Bioscience. Mr. Kendall also supports ARCH Technical Services, where he has encouraged breakthrough innovations in electronics, sustainable materials, energy, and more via corporate partnering and investment.

A chemical engineer and synthetic biologist by training, Mr. Kendall was an early employee with LS9, Inc. (acquired by Genomatica), where he developed an automated experimentation and modeling platform for cell engineering. He next scaled commercial processes for Cobalt Technologies. Mr. Kendall is a recipient of the President’s Green Chemistry Challenge Award. He holds a B.S. and M.S. in Chemical Engineering from Stanford University, where he worked with Jim Swartz on cell-free protein synthesis, and an M.B.A. from the University of Chicago.

ALL Partners, Associates, Affiliates